Gilead projects $107M Q1 earnings headwind due to recent R&D deals
Source: SeekingAlpha
2026-04-10 10:09:32 ET
More on Gilead Sciences
- Gilead Sciences Is Doubling Down On Acquisitions
- Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
- Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion - Slideshow
- SA analyst upgrades/downgrades: PLTR, RIVN, GILD, INTC
- Gilead to acquire Tubulis GmbH for $5B
Read the full article on Seeking Alpha
For further details see:
Gilead projects $107M Q1 earnings headwind due to recent R&D deals
Arcellx Inc.
NASDAQ: ACLX
ACLX Trading
0.04% G/L:
$115.08 Last:
1,195,659 Volume:
$115.04 Open:
ACLX Latest News
March 16, 2026 07:33:01 pm
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
ACLX Stock Data
$3,888,009,846
37,694,730
1.62%
80
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
